Herantis Pharma - CDNF early data show biological promise
Herantis has announced top-line data from the first part of the Phase I/II clinical trial on novel asset CDNF in Parkinson’s disease (PD). Data reported for the first six months are preliminary in this first-in-human clinical study for this novel MOA drug class. Safety and tolerability have been confirmed but, interestingly, the early biological efficacy signals (seen on PET imaging) serve as validation of the scientific hypothesis for CDNF’s potential neuroprotective and neurorestorative effects. Herantis expects data from the six-month extension study in Q320. It raised gross cash of €10m through two equity issues in 2019, which has extended the cash runway to key value inflection points. We increase our valuation to €66.9m (€10.0/share).Herantis Pharma Oyj. Herantis Pharma Oyj is a Finland-based pharmaceutical company. It is engaged in the development of treatments for unmet clinical needs, such as dry eye syndrome, Parkinson's disease and secondary lymphedema, among others. The Company's product development portfolio includes: Cis-UCA eye drops for dry eye, CDNF for Parkinson's disease, Lymfaticin aimed at secondary lymphedema, Cis-UCA emulsion cream for atopis dermatitis, and CDNF targeting Amyotrophic Lateral Sclerosis.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.